CARA - Cara inks U.S. commercialization pact with Vifor Pharma for IV Korsuva

Cara Therapeutics (CARA) jumps 12% in premarket on moderate volume, after announcing a profit-sharing deal with Vifor Pharma (GNHAF), for the commercialization of intravenous ((IV)) Korsuva as a treatment of chronic kidney disease-associated pruritus in the U.S. dialysis market for non-Fresenius Medical Care clinics.Cara will get 60% of the profits and Vifor will take the remaining 40%.Vifor will pay $100M to Cara in upfront cash and $50M in equity; Cara is eligible for an additional equity investment of $50M upon U.S. approval of IV Korsuva, and milestone payments of $240M.NDA submission for IV Korsuva expected during this quarter.8K

For further details see:

Cara inks U.S. commercialization pact with Vifor Pharma for IV Korsuva